Recursion Pharmaceuticals Inc (RXRX)
5.70
-0.05
(-0.87%)
USD |
NASDAQ |
Nov 22, 16:00
5.75
+0.05
(+0.88%)
After-Hours: 20:00
Recursion Pharmaceuticals Cash from Financing (Quarterly): 16.46M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 16.46M |
| June 30, 2024 | 263.12M |
| March 31, 2024 | 13.90M |
| December 31, 2023 | 80.66M |
| September 30, 2023 | 53.76M |
| June 30, 2023 | 3.787M |
| March 31, 2023 | 1.922M |
| December 31, 2022 | 147.26M |
| September 30, 2022 | 2.337M |
| June 30, 2022 | 2.668M |
| Date | Value |
|---|---|
| March 31, 2022 | 2.084M |
| December 31, 2021 | 3.796M |
| September 30, 2021 | -11.10M |
| June 30, 2021 | 463.70M |
| March 31, 2021 | 2.134M |
| December 31, 2020 | 10.04M |
| September 30, 2020 | 229.72M |
| June 30, 2020 | 0.382M |
| March 31, 2020 | 5.997M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-11.10M
Minimum
Sep 2021
463.70M
Maximum
Jun 2021
68.03M
Average
5.997M
Median
Mar 2020
Cash from Financing (Quarterly) Benchmarks
| Revance Therapeutics Inc | -6.087M |
| NovaBay Pharmaceuticals Inc | 2.089M |
| Palatin Technologies Inc | -0.127M |
| iBio Inc | -0.162M |
| Theriva Biologics Inc | 3.716M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -59.22M |
| Cash from Investing (Quarterly) | -4.562M |
| Free Cash Flow | -335.64M |
| Free Cash Flow Per Share (Quarterly) | -0.2257 |
| Free Cash Flow to Equity (Quarterly) | -61.49M |
| Free Cash Flow to Firm (Quarterly) | -63.79M |
| Free Cash Flow Yield | -23.96% |